Comparative Pharmacology
Head-to-head clinical analysis: DURAGESIC 100 versus LERITINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAGESIC 100 versus LERITINE.
DURAGESIC-100 vs LERITINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pure opioid agonist that binds to mu-opioid receptors in the CNS, mimicking endogenous endorphins to inhibit pain transmission. Also interacts with kappa and delta receptors. Therapeutic effects include analgesia, sedation, and euphoria.
LERITINE (anileridine) is a synthetic opioid analgesic that acts as a mu-opioid receptor agonist, modulating pain perception and emotional response to pain.
Transdermal patch; initial dose based on prior opioid use: for opioid-naive patients, 12 mcg/h every 72 hours; for opioid-tolerant patients, convert using equianalgesic tables; maximum dose 100 mcg/h per patch; apply to non-irritated, non-irradiated skin on chest, back, flank, or upper arm.
Adults: 25-50 mg orally every 6 hours as needed for pain; not to exceed 200 mg/day.
None Documented
None Documented
Terminal elimination half-life approximately 20–27 hours after transdermal system removal (range 13–25 hours in healthy adults; prolonged in elderly, hepatic impairment, and cachexia).
2-3 hours (terminal half-life in adults; may be prolonged in hepatic impairment or elderly, dosing adjustments recommended)
Renal (primarily as metabolites, <10% unchanged fentanyl); fecal (about 9% of dose).
Renal (70-90% as unchanged drug and metabolites); biliary/fecal (10-30%)
Category C
Category C
Opioid Analgesic
Opioid Analgesic